Live
BioPharma DiveCytospire hauls in $83M for a new type of T cell engagerSamsung BiologicsSamsung Biologics Labor Talks Break Down, Gap Remains - thelec.netSiemens HealthineersCDC HoSt-TT certification for Siemens Healthineers total testosterone test expands patient access to gold standard equivalent results - News-MedicalSamsung BiologicsSamsung Biologics union continues first general strike, demands higher wages and performance-based pay - Korea JoongAng DailyFierceBiotechPrivate Swiss biotechs hit record funding amid slowdown in public financingSamsung BiologicsSamsung Biologics' strike enters 5th day - Yonhap News AgencyeLifeAre kinocilia motile?eLifeHuman adherent cortical organoids in a multi-well formatEndpoints NewsVertex drops mRNA cystic fibrosis program over 'tolerability' issuesBio-RadBio-Rad Navigates Academic Headwinds and Geopolitical Shifts in Q1 2026 Financial Results - Lab ManagerFierceBiotechVertex drops Moderna-partnered inhaled cystic fibrosis candidate after unresolved tolerability issues
BioPharma Dive Jan 23, 2026

Sanofi to seek approval of touted eczema drug despite mixed results

Sanofi to seek approval of touted eczema drug despite mixed results

Body unavailable. Use the original source.